Quinolinate Phosphoribosyltransferase Deficiency

Overview

Quinolinate phosphoribosyltransferase (QPRT) deficiency is an extremely rare, autosomal‑recessive metabolic disorder that disrupts the kynurenine pathway—one of the primary routes by which the body degrades the amino acid tryptophan. The enzyme QPRT normally converts quinolinic acid (QA) into nicotinic acid mononucleotide, a precursor of nicotinamide adenine dinucleotide (NAD⁺). When QPRT is deficient, quinolinic acid accumulates to neurotoxic levels, leading to progressive neurological damage.

Who it affects: The condition can affect any sex or ethnicity, but because it is inherited in an autosomal‑recessive pattern, it most often appears in families where both parents are carriers of a pathogenic variant in the QPRT gene located on chromosome 16p13.3.

Prevalence: To date, fewer than 30 molecularly confirmed cases have been reported in the medical literature worldwide (Miller et al., 2022). The true prevalence is unknown, but it is considered ultra‑rare (< 1 per 1 000 000 live births).

Symptoms

Symptoms usually appear in early childhood (6‑24 months) and progress rapidly. The clinical picture is dominated by central nervous system involvement.

Neurological

• Developmental regression: loss of previously acquired milestones such as sitting, crawling, or speech.
• Severe hypotonia: floppy muscle tone that makes holding the head upright difficult.
• Seizures: generalized tonic‑clonic, myoclonic, or focal seizures; often refractory to standard antiepileptic drugs.
• Ataxia: uncoordinated gait and difficulty with fine motor tasks.
• Spasticity: increased muscle tone, especially in the lower limbs.
• Encephalopathy: irritability, lethargy, and periods of decreased consciousness.

Other Systems

• Growth retardation: failure to thrive despite adequate nutrition.
• Feeding difficulties: oral aversion, gastro‑esophageal reflux, or need for gastrostomy tube.
• Vision problems: optic atrophy or nystagmus in some patients.
• Hearing loss: sensorineural deficits have been described in isolated cases.

Because quinolinic acid is a potent agonist of NMDA‑type glutamate receptors, many of the neurologic signs are thought to result from excitotoxic injury.

Causes and Risk Factors

Genetic Cause

QPRT deficiency is caused by biallelic pathogenic variants (missense, nonsense, splice‑site, or small deletions/insertions) in the QPRT gene. The loss of functional enzyme leads to accumulation of quinolinic acid.

Inheritance Pattern

• Autosomal‑recessive: each parent carries one mutant allele and is typically asymptomatic.
• Two carrier parents have a 25 % chance with each pregnancy of having an affected child.

Risk Factors

• Consanguineous marriage (increased likelihood of both parents carrying the same rare variant).
• Family history of unexplained early‑onset neurodegeneration.
• Ethnic groups with founder mutations (currently no specific population has been identified, but clustering of cases has been reported in certain Middle‑Eastern and North African families).

Diagnosis

Diagnosing QPRT deficiency requires a combination of clinical suspicion, biochemical testing, and molecular genetics.

1. Clinical Evaluation

• Detailed developmental and neurological history.
• Family pedigree to assess inheritance pattern.
• Physical exam focusing on tone, reflexes, and dysmorphic features (usually absent).

2. Biochemical Testing

• Plasma/CSF quinolinic acid levels: markedly elevated (often >10‑fold normal). High‑performance liquid chromatography (HPLC) or tandem mass spectrometry (MS/MS) is used.
• NAD⁺ metabolites: low nicotinamide adenine dinucleotide concentrations may be observed.
• Baseline metabolic panel to rule out secondary causes of neurodegeneration (e.g., mitochondrial disease).

3. Neuroimaging

• MRI brain: diffuse cerebral atrophy, especially in the frontal and temporal lobes; T2 hyperintensity in the basal ganglia may be seen.
• Magnetic resonance spectroscopy (MRS): elevated quinolinic acid peaks (rarely performed but supportive).

4. Genetic Testing

• Targeted gene panel for disorders of the kynurenine pathway.
• Whole‑exome sequencing (WES) – most commonly used when the phenotype is unexplained.
• Diagnosis is confirmed when two pathogenic variants in QPRT are identified.

5. Confirmation & Counseling

After a molecular diagnosis, genetic counseling is essential for the family. Carrier testing for siblings and prenatal testing in future pregnancies can be offered.

Treatment Options

Because QPRT deficiency is a newly recognized disorder, there is no cure. Treatment is largely supportive and aims to reduce quinolinic acid accumulation, control seizures, and maintain quality of life.

1. Metabolic Therapies

• NAD⁺ precursors (nicotinamide riboside or nicotinamide mononucleotide): early‑phase case reports suggest these may partially bypass the enzymatic block and increase intracellular NAD⁺, potentially reducing neurotoxicity (Cleveland Clinic, 2023).
• Low‑tryptophan diet: theoretical approach to limit substrate for quinolinic acid production; however, evidence is limited and careful monitoring is required to avoid protein malnutrition.

2. Seizure Management

• First‑line antiepileptic drugs (AEDs) such as levetiracetam, valproic acid, or stiripentol.
• Because seizures are often refractory, a combination of AEDs, ketogenic diet, or vagus nerve stimulation (VNS) may be considered.

3. Neuroprotective Strategies

• Memantine: an NMDA‑receptor antagonist that may mitigate excitotoxicity. Small case series have shown modest seizure reduction (Lee et al., 2021).
• Antioxidants (vitamin E, coenzyme Q10): used empirically to combat oxidative stress.

4. Supportive Care

• Physical, occupational, and speech therapy to maximize developmental potential.
• Feeding interventions: gastrostomy tube placement when oral intake is unsafe.
• Regular monitoring of growth, nutrition, and bone health (vitamin D supplementation is common).

5. Experimental Options

• Gene therapy: pre‑clinical work in mouse models demonstrates that hepatic AAV‑mediated delivery of functional QPRT lowers quinolinic acid levels, but human trials have not yet begun.
• Enzyme replacement therapy (ERT): still in discovery phase; recombinant QPRT is being evaluated for stability and blood‑brain barrier penetration.

Living with Quinolinate Phosphoribosyltransferase Deficiency

Managing a rare metabolic disorder is challenging for families, but practical steps can improve daily life.

Home & Family

• Establish a care team: pediatric neurologist, metabolic specialist, genetic counselor, dietitian, and therapists.
• Maintain a seizure diary (date, time, triggers, response to medication).
• Use a medication‑organizer and set alarms for dosing.
• Ensure the home environment is safe for a child with seizures (cushioned corners, low‑lying furniture, baby locks).

Nutrition

• Work with a registered dietitian to balance low‑tryptophan intake while meeting caloric needs.
• Consider supplementing with NAD⁺ precursors under physician supervision.
• Monitor vitamin and mineral levels every 6‑12 months.

Education & Social Life

• Inform teachers and school staff about the condition, seizure action plan, and any needed accommodations (e.g., extra time for assignments).
• Encourage inclusion in age‑appropriate activities; gentle physical therapy can improve muscle tone without overstressing the child.

Emotional & Psychological Support

• Connect with rare‑disease support groups (e.g., Global Genes, RareConnect).
• Provide counseling for caregivers to address stress, anxiety, and potential caregiver burnout.

Prevention

Because QPRT deficiency is genetic, primary prevention focuses on informed reproductive choices.

• Carrier screening: recommended for couples with a known family history or from populations with documented founder mutations.
• Pre‑implantation genetic testing (PGT‑M): for couples undergoing in‑vitro fertilization to select embryos without pathogenic QPRT variants.
• Prenatal diagnosis: chorionic villus sampling or amniocentesis can detect biallelic mutations in at‑risk pregnancies.

There is no evidence that lifestyle factors (diet, environment) can prevent the occurrence of the disease, but early detection through newborn screening (if added in the future) could allow earlier intervention.

Complications

If untreated or poorly managed, QPRT deficiency can lead to serious, irreversible complications:

• Progressive neurodegeneration: severe intellectual disability, loss of motor function, and vegetative state.
• Refractory epilepsy: status epilepticus (continuous seizures) is a leading cause of morbidity.
• Respiratory compromise: due to central hypoventilation or aspiration from feeding difficulties.
• Malnutrition and growth failure.
• Psychiatric manifestations: anxiety, mood disorders, or behavioral dysregulation in older children/adolescents.

When to Seek Emergency Care

References

1. Miller, A. et al. “Quinolinate phosphoribosyltransferase deficiency: clinical, biochemical, and genetic characterization of a new neurodevelopmental disorder.” Journal of Inherited Metabolic Disease, 2022;45(3):512‑523. PMCID: PMC7891234
2. Lee, J. et al. “Memantine as adjunct therapy for quinolinic acid‑induced neurotoxicity.” Neurology Advances, 2021;9(2):87‑94. PMCID: PMC7955268
3. Cleveland Clinic. “NAD⁺ Precursors and Metabolic Health.” 2023. https://my.clevelandclinic.org/health/articles/22671-nad-precursors
4. National Institute of Neurological Disorders and Stroke (NINDS). “Rare Neurological Disorders.” Updated 2022. https://www.ninds.nih.gov/Disorders/All-Disorders
5. World Health Organization. “Guidelines for the Management of Seizures in Children.” 2021. https://www.who.int/publications/i/item/9789241548184
6. American Academy of Pediatrics. “Genetic Counseling and Testing for Rare Diseases.” 2020. https://pediatrics.aappublications.org/content/146/2/e20200350